Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6P4I2
UPID:
WDR73_HUMAN
Alternative names:
-
Alternative UPACC:
Q6P4I2; Q96JZ1; Q9P0B7
Background:
WD repeat-containing protein 73 plays a crucial role in cellular processes by regulating microtubule organization and dynamics. This protein's involvement in microtubule dynamics suggests its importance in cell division, intracellular transport, and cellular structure maintenance. Its precise mechanisms, however, remain to be fully elucidated, making it a subject of significant scientific interest.
Therapeutic significance:
WD repeat-containing protein 73 is linked to Galloway-Mowat syndrome 1, a severe condition characterized by nephrotic syndrome, neurological abnormalities, and early childhood mortality. Understanding the role of WD repeat-containing protein 73 could open doors to potential therapeutic strategies for this devastating disease.